[Federal Register Volume 79, Number 43 (Wednesday, March 5, 2014)]
[Notices]
[Pages 12512-12515]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-04771]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

Software for 3D Spectral Fingerprint Based Consensus Modeling Using 
Orthogonal PLS and Tanimoto Similarity KNN Techniques

    Description of Technology: This technology is a software tool for 
improving molecular modeling. The software addresses data matrices 
processed in rows instead of columns and the result of these approaches 
are combined. To process data in rows, the technique uses a measure of 
similarity known as ``Tanimoto Similarity'' operating on pairs of 
objects. The property values of the top most similar objects are 
normalized and used as coefficients to predict the property of 
interest. These predictions can then be used in combination with the 
predictions obtained by multivariate techniques to improve the quality 
of the consensus model in comparison to the individual predictions. 
Since, in the case of multivariate techniques, the information is 
accessed in columns, while for the similarity based technique it is 
accessed in rows, the two types of techniques provide complementary 
information. Thus, more useful information can be extracted from the 
same data matrix. Also contemplated is the use of consensus modeling by 
letting two algorithms (PLS and KNN) operate on descriptor matrices of 
different size. If each of these matrices is processed by a different 
model building algorithm and a consensus model between two or more such 
individual models is built, the resulting model would benefit from 
both: i) the partial orthogonality of the modeling techniques and ii) 
the complementarity of the information contained in 3D-SDAR matrices of 
different granularity.
    Potential Commercial Applications:

 Drug Design
 Drug Development

    Competitive Advantages:

 Matrix processing of molecules of biological interest
 High Fit-Activity Prediction capacity

    Development Stage:

 Early-stage
 In vitro data available

    Inventors: Svetoslav H. Slavov, Jon G. Wilkes, Rick Beger, Dan A. 
Buzatu, Bruce A. Pearce (all of FDA)

    Publications:

    1. Slavov SH, et al. \13\C NMR-distance matrix descriptors: 
optimal abstract 3D space granularity for predicting estrogen 
binding. J Chem Inform Model. 2012 Jul 23;52(7):1845-64. [PMID 
22681591]
    2. Slavov SH, et al. Complementary PLS and KNN algorithms for 
improved 3D-QSDAR consensus modeling of AhR binding. J Cheminform. 
2013 Nov 21;5(1):47-62. [PMID 24257141]
    3. Stoyanova-Slavova IB, et al. PLS and KNN algorithms for 
improved 3D-QSDAR consensus modeling of acute toxicity. Environ 
Toxicol Chem. 2014 Jan 27 (Epub ahead of print). [PMID 24464801]

    Intellectual Property: HHS Reference No. E-015-2014/0--Software 
Materials. Patent protection is not being pursued for this 
technology.

    Related Technologies:

 HHS Reference No. E-209-1999/1--US Patent 6,898,533 issued 
24 May 2005
 HHS Reference No. E-297-2001/0--US Patent 7,996,156 issued 
09 Aug 2011

    Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-6019; 
[email protected].

    Collaborative Research Opportunity: The Food and Drug 
Administration is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize Molecular Modeling/Drug Design. For 
collaboration opportunities, please contact Ashley Groves at 870-
543-7956.

Multivalent, Multiple-Antigenic-Peptides for Serological Detection of 
HIV-1 Groups -M, -N, -O, and HIV-2

    Description of Technology: This CDC-developed invention pertains 
to multivalent antigenic peptides (MAPs) that can be used in a 
variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1 
and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2 
is subdivided into subtypes A and B. Within HIV -1 group M, several 
different subtypes and numerous forms of recombinant viruses exist. 
To detect all types, groups, and subtypes of HIV by serological 
methods, a mixture of antigens derived from different viral strains 
representing different HIV types and subtypes is needed. However, 
due to the competition and dilution effect, mixing multiple antigens 
may reduce the amount of individual antigen bound to the solid phase 
and lead to a reduction in assay sensitivity.
    It is known that MAPs, which contain multiple branches of an 
oligopeptide sequence, are more antigenic than the corresponding 
single chain linear peptides. The MAPs encompassed by this 
technology contain multiple branches of oligopeptides of different 
sequences, derived from HIV-1 group M, N, O, and HIV-2. Thus, 
depending on the peptide sequences incorporated, a single MAP can be 
used to detect HIV-1 group M alone, HIV-2 alone, or to 
simultaneously detect HIV-1 groups M, N, O, and HIV-2 with high 
sensitivity and specificity.

    Potential Commercial Applications:

 Diagnostic test for HIV-1 and/or HIV-2 infection
 Blood and plasma donation screening
 HIV/AIDS surveillance and monitoring programs

    Competitive Advantages:

 Lateral flow assays for HIV detection and discrimination
 On-site, point-of-care testing and diagnosis
 Easily formulated as an ELISA kit for commercial or 
research applications
 Technology can be used to develop a rapid, low-cost method 
of determining HIV status for home-use or low-resource settings

    Development Stage: In vitro data available
    Inventor: Chou-Pong Pau (CDC)

    Publications:

1. Granade TC, et al. Rapid detection and differentiation of 
antibodies to HIV-1 and HIV-2 using multivalent antigens and 
magnetic immunochromatography testing. Clin Vaccine Immunol. 2010 
Jun;17(6):1034-9. [PMID 20410326]
2. Pau C, et al. Chimeric multiple antigenic peptides for the 
simultaneously detection of specific antibodies to HTV-1 groups M, 
N, O, and HIV-2. J Immunol Methods. 2007 Jan 10;318(1-2):59-64. 
[PMID 17169369]

[[Page 12513]]

3. Kim P and Pau CP. Comparing tandem repeats and multiple antigenic 
peptides as the antigens to detect antibodies by enzyme immunoassay. 
J Immunol Methods. 2001 Nov 1;257(1-2):51-4. [PMID 11687238]

    Intellectual Property: HHS Reference No. E-604-2013/0--Research 
Tool. Patent protection is not being pursued for this technology.

    Related Technologies:

 HHS Reference No. E-052-2013/0
 HHS Reference No. E-053-2013/0
 HHS Reference No. E-173-2013/0
 HHS Reference No. E-232-2013/0
 HHS Reference No. E-259-2013/0
 HHS Reference No. E-294-2013/0
 HHS Reference No. E-357-2013/0
 HHS Reference No. E-358-2013/0
 HHS Reference No. E-522-2013/0
 HHS Reference No. E-555-2013/0
 HHS Reference No. E-638-2013/0

    Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937; 
[email protected].

Recombinant, Multivalent Malarial Antigens for Development of 
Therapeutics, Diagnostics and/or a Multistage Vaccine for Plasmodium 
falciparum

    Description of Technology: This CDC-generated technology relates 
to a recombinant, multivalent and multi-stage malaria vaccine and, 
more specifically, to antigenic proteins useful for preventing or 
treating Plasmodium falciparum malarial infections. Malaria 
continues to be a public health problem throughout the world and P. 
falciparum is often identified as the cause of the most severe forms 
of the disease. Ideally, an effective malaria vaccine would contain 
a combination of key antigens/epitopes from different stages of the 
pathogen's complex life-cycle. This approach to vaccination would 
likely result in the induction of both humoral and cellular immunity 
for optimal efficacy and a broad scope of protection.
    This technology entails a multi-stage vaccine against malaria 
that is effective in inhibiting reproductive growth of the parasite 
within a human or animal after initial infection. Further, the 
technology includes antibodies against a recombinant protein 
containing antigenic epitopes to varied life-cycle stages of a 
malarial Plasmodium species. These antigens and antibodies may be 
useful as research tools or diagnostic reagents for the detection 
and diagnosis of P. falciparum at a number of different life-cycle 
stages within a biological sample.

    Potential Commercial Applications:

 Malaria vaccine development
 Useful for malaria vaccination and surveillance programs
 Military, foreign service applications
 Mitigation of zoonotic disease transmission and livestock 
morbidity, especially within South Asia

    Competitive Advantages:

 Single vaccine confers immunity against the malarial 
parasite at multiple life cycle stages, increasing the chances of 
neutralizing sustained infection
 In vivo animal studies demonstrate vaccine efficacy

    Development Stage:

 In vitro data available
 In vivo data available (animal)

    Inventors: Altaf A. Lal (CDC), Ya-Ping Shi (CDC), Seyed P. 
Hasnain (National Institute of Immunology--India)
    Publication: Shi YP. Immunogenicity and in vitro protective 
efficacy of a recombinant multistage Plasmodium falciparum candidate 
vaccine. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1615-20. [PMID: 
9990073]

    Intellectual Property: HHS Reference No. E-451-2013/0--

 US Patent No. 6,828,416 issued 07 Dec 2004
 Various international patent applications pending or issued

    Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937; 
[email protected].

Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis 
of Atmospheric or Aerosolized Particulate Mixtures

    Description of Technology: This technology pertains to monitors 
for measuring the mass concentration of ambient particulate matter 
in an atmosphere containing both larger/coarser (e.g., respirable 
dust) and smaller/finer (sub-micrometer particles such as diesel 
particulate matter--DPM) particulate mixtures. The monitoring device 
can be configured for operation with a controller unit adapted to 
ionization sensor and/or light-scattering modules. The controller 
translates the sensor output signal into a quantifiable value, 
determining mass concentration of particulate matter within the 
ionization chamber. For example, practical applications of this 
monitor/analysis technology would easily extend to use in mining 
operations (where both DPM and respirable dust exist in abundance), 
industrial manufacturing facilities, and anywhere that frequent or 
extended exposure to fuel-combustion exhaust or airborne pollution 
is a concern. Further, by virtue of its ability to distinguish 
``fire smoke'' from other aerosols that may be present, the device 
also has significant potential for use in early-warning fire 
detection.

    Potential Commercial Applications:

 Airborne particle monitor for mining and industrial 
manufacturing operations
 Addressing emissions control standards and regulations
 Early-warning fire detection in locations where traditional 
smoke-detector use is impractical

    Competitive Advantages:

 Inexpensive and simple to implement
 Device provides continuous, simultaneous, and independent 
measurement of both respirable dust and diesel particulate matter 
(DPM) mass concentrations
 Previous particulate counting technologies are both 
expensive and cannot provide accurate quantification of coarse/fine 
aerosol mixtures, concentrations

    Development Stage:

 In situ data available (on-site)
     Prototype
    Inventors: Charles D. Litton, Jon C. Volkwein, William H. 
Schiffbauer (all of CDC)

    Intellectual Property: HHS Reference No. E-240-2013/0--US Patent 
No. 6,965,240 issued 27 Mar 2003
    Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937; 
[email protected].

A Targeted Therapy for the Activated B Cell-Like Subtype of Diffuse 
Large B Cell Lymphoma

    Description of Technology: NIH scientists have developed novel 
peptides that specifically target the activated B cell like (ABC) 
subtype of diffuse large B cell lymphoma (DLBCL), which is the least 
curable form of this aggressive lymphoma.
    ABC DLBCL is characterized by constitutive NF-kB pathway 
activation, which depends on the binding of two protein molecules, 
RNF31 and RBCK1. These cell-permeable peptides compete against 
endogenous RNF31, therefore inhibit the NF-kB induction pathway and 
kill the malignant cells.
    This technology would be a potential targeted therapy for ABC 
DLBCL, and could be combined with radiation or chemotherapy for ABC 
DLBCL or other cancers. Additionally, these peptides could also be 
applied to treat rheumatoid arthritis, chronic autoinflammation, 
systemic lupus erythematosus, Crohn's inflammatory bowel disease, or 
psoriasis.
    Potential Commercial Applications:

 Targeted therapies for ABC DLBCL.
 Combination cytotoxic chemotherapies for ABC DLBCL.
 Treatment for other cancers or autoimmune/inflammatory 
diseases that depend upon the function of RNF31 and RBCK1 
combination.

    Competitive Advantages:

 Novel composition of inhibitors for ABC DLBCL.
 Novel targeted drug to ABC DLBCL.
 Effective therapies targeting at NF-kB pathway.

Development Stage:

 Early-stage
 In vitro data available

    Inventors: Louis M. Staudt, Yibin Yang, Federico Bernal (all of 
NCI)
    Publication: Yang Y, et al. Essential Role of the Linear 
Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare 
Germline Polymorphisms. Cancer Discov. 2014 Feb 3 (Epub ahead of 
print). [PMID 24491438]
    Intellectual Property: HHS Reference No. E-035-2013/0--US 
Provisional Application No. 61/789,064 filed 15 March 2013
    Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587; 
[email protected].
    Collaborative Research Opportunity: The National Cancer 
Institute is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize the inhibitors of the LUBAC ubiquitin 
ligase for the therapy of lymphoma and autoimmune diseases. For 
collaboration

[[Page 12514]]

opportunities, please contact John D. Hewes, Ph.D. at 
[email protected].

Mutation Based Control Plasmids for Standardizing Cancer Genomic 
Diagnostic Assays

    Description of Technology: To date, there are no widely accepted 
standards and controls for multi-analyte based diagnostic assays. 
The ability to compare the accuracy of different types of assay 
results and to utilize in process controls is hampered by the lack 
of availability of such standards/controls. Variations resulting 
from different platforms, methodologies, and bioinformatics analyses 
therefore create error in the interpretation of assay reports and 
different results may occur when testing for the presence or absence 
of specific gene mutations or biomarkers.
    This technology includes a library of plasmids that can be used 
to test for and control for accuracy, sensitivity, and specificity 
and reproducibility within an assay and across different assays or 
laboratories and platforms. These standards consist of normal human 
reference genomic DNA that have engineered to contain known sequence 
variations representing somatic mutations of interest to cancer 
management. The plasmids contain approximately 1000 bases of human 
sequence. Each inserted sequence carries a specific mutation of 
interest within the appropriate genomic locus and a mutation 
adjacent alien barcode. The plasmids can be mixed with non-mutant 
genomes to create exact variant to normal allele frequencies for 
limit of detection studies. The alien barcode unequivocally 
indicates the detected mutation is from the plasmid spiked into a 
test human specimen. If needed for certain applications the barcode 
can be left out of design.
    Potential Commercial Applications:

 Quantified standards for scientists to compare, optimize 
and/or validate assays
 Assess specificity, sensitivity, accuracy and limit 
detection of artifacts during assay development
 Internal in process run controls to monitor assay 
performance

    Competitive Advantages:

 Reference materials for comparing results of assays 
performed by different platforms, operators, times, and sites
 Ability to uniquely distinguish plasmid control mutations 
spiked directly into unknown samples by alien barcode
 No limit in the number and types of mutation plasmids 
introduced into the test human specimen, unlike engineered cell line 
genome based mutation controls
 Easy design and manufacture process

    Development Stage: In vitro data available
    Inventors: Chih-Jian Lih, Paul Williams, David Sims, Michele 
Mehaffey (all of NCI)
    Publications: Manuscripts in preparation.
    Intellectual Property: HHS Reference No. E-265-2012/0--Research 
Tool. Patent protection is not being pursued for this technology.
    Licensing Contact: Jennifer Wong, M.S.; 301-435-4633; 
[email protected]
    Collaborative Research Opportunity: The National Cancer 
Institute, Cancer Diagnosis Program, is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize Mutation 
Based Control Plasmids for Standardizing Cancer Genomic Diagnostic 
Assays. For collaboration opportunities, please contact John Hewes, 
Ph.D. at [email protected].

Use of Soluble CD27 as Potential Immunotherapy and a Diagnostic and 
Prognostic Serum Biomarker for Solid Tumors

    Description of Technology: The present invention discloses 
methods for diagnosing a patient with a solid tumor or a 
predisposition to developing a solid tumor, a patient's suitability 
for immunotherapy and monitor disease progression in a patient 
undergoing treatment for a solid tumor, such as a prostate or 
colorectal tumor, by measuring the amount of soluble CD27 (sCD27) 
present in a serum sample obtained from a patient and detecting the 
amount of sCD27present in the serum sample. Additionally, sCD27 can 
also be developed an immunotherapeutic product. Such product will 
constitute the administration of a therapeutically effective amount 
of sCD27 or a functional 15 fragment thereof that is capable of 
stimulating a patient's immune system.
    CD27 is a tumor necrosis factor receptor. A soluble form of CD27 
(sCD27), is a 32-kD protein identical to the extracellular domain of 
membrane-bound CD27. CD27's role in T cell activation has been 
previously demonstrated.
    Potential Commercial Applications:

 Serum biomarker for diagnosis, prognosis and therapeutic 
response.
 Can potentially be developed into an immunotherapeutic 
product.

    Competitive Advantages:

 Potentially can be used with clinically proven platforms.
 Can be developed into a minimally invasive diagnostic test 
using patient's blood sample.

    Development Stage:

 Early-stage

 In vitro data available

    Inventors: Jeffrey Schlom and Jianping Huang (NCI)
    Publication: Huang J, et al. Soluble CD27-pool in humans may 
contribute to T cell activation and tumor immunity. J Immunol. 2013 
Jun 15;190(12):6250-8. [PMID 23677477]
    Intellectual Property: HHS Reference No. E-005-2011/0--US Patent 
Application No. 61/824,898 filed 17 May 2013
    Licensing Contact: Sabarni Chatterjee, Ph.D., MBA; 301-435-5587; 
[email protected].
    Collaborative Research Opportunity: The National Cancer 
Institute, Laboratory of Metabolism, is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize a non-
invasive assay for the detection of colorectal cancer. For 
collaboration opportunities, please contact John D. Hewes, Ph.D. at 
[email protected].

The Use of alpha-4 beta-7 integrin Inhibitors To Inhibit HIV 
Transmission and Infection

    Description of Technology: This invention involves the use of 
inhibitors of alpha-4 beta-7 ([alpha]4[beta]7) integrin to inhibit 
HIV transmission/infection, as a prophylactic to inhibit onset of 
the acute stage of HIV infection or to treat HIV infection. The 
[alpha]4[beta]7 integrin inhibitors were previously developed for 
use in other diseases, such as multiple sclerosis or inflammatory 
bowel disease.
    [alpha]4[beta]7 integrin is a multifaceted target for HIV 
infection and recent studies indicate that it is important for 
establishing HIV infection through multiple paths. Studies indicate 
that: (1) CD4 T-cells present in vaginal and anal mucosa have high 
levels of [alpha]4[beta]7 integrin, making CD4 T-cells permissive to 
HIV infection; (2) [alpha]4[beta]7 integrin is important for cell to 
cell transmission of HIV; (3) [alpha]4[beta]7 integrin is used to 
dysregulate the host humoral response to HIV; and (4) HIV acts on 
a4b7 integrin through an epitope in V2 loop of GP120, identified as 
important for HIV vaccine protection. Additionally, primate studies 
indicate that [alpha]4[beta]7 integrin inhibition of HIV infection 
preserves gut-associated lymphoid tissue (GALT) generally destroyed 
during the acute phase of HIV infection.
    Potential Commercial Applications: Prevention and treatment of 
HIV infection
    Competitive Advantages:

 [alpha]4[beta]7 integrin is a multifaceted target for HIV 
infection
 Previously developed [alpha]4[beta]7 integrin inhibitors 
can be used for a new purpose

    Development Stage:

 Pre-clinical
 In vitro data available
 In vivo data available (animal)
    Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci, Diana 
Goode (all of NIAID)
    Publications:

1. Martinelli E, et al. The frequency of 
[alpha]4[beta]7\high\ memory CD4\+\ T cells 
correlates with susceptibility to rectal simian immunodeficiency 
virus infection. J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):325-
31. [PMID 23797688]
2. Nawaz F, et.al. The genotype of early-transmitting HIV gp120s 
promotes [alpha]4[beta]7-reactivity, revealing 
[alpha]4[beta]7\+\/CD4\+\ T cells as key 
targets in mucosal transmission. PLoS Pathog. 2011 
Feb;7(2):e1001301. [PMID 21383973]
3. Cicala C, et al. The integrin 
[alpha]4[beta]7 forms a complex with cell-
surface CD4 and defines a T-cell subset that is highly susceptible 
to infection by HIV-1. Proc Natl Acad Sci U S A. 2009 Dec 
8;106(49):20877-82. [PMID 19933330]
4. Arthos J, et al. HIV-1 envelope protein binds to and signals 
through integrin [alpha]4[beta]7, the gut 
mucosal homing receptor for peripheral T cells. Nat Immunol. 2008 
Mar;9(3):301-9. [PMID 18264102]

    Intellectual Property:

 HHS Reference No. E-055-2007/0--US Provisional Patent 
Application No. 60/873,884 filed 07 Dec 2006
 HHS Reference No. E-055-2007/1--US Provisional Patent 
Application No. 60/920,880 filed 30 Mar 2007

[[Page 12515]]

 HHS Reference No. E-055-2007/2--US Provisional Patent 
Application No. 60/957,140 filed 21 Aug 2007
 HHS Reference No. E-055-2007/3--PCT Patent Application No. 
PCT/US2007/086663 filed 06 Dec 2007, which published as WO 2008/
140602 on 20 Nov 2008, and corresponding European Application No. 
07874349.9; US Patent Application No. 12/518,035 filed 05 Jun 2009

    Licensing Contact: Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 
301-435-4507; [email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability 
or interest from parties interested in collaborative research to 
further develop, evaluate or commercialize alpha-4 beta-7 integrin 
inhibitors. For collaboration opportunities, please contact Bill 
Ronnenberg, JD/MIP, MS at 301-451-3522 or [email protected].

Beta-Amyloid and Tau Fibril Positron Emissions Tomography (PET) Imaging 
Agents

    Description of Technology: The invention relates to two novel 
classes of compounds useful as radioligands for in vivo imaging of 
beta-amyloid fibrils, peptides and plaques in humans. Beta-amyloid 
peptide deposition in the brain is a pathological feature of 
Alzheimer's disease (AD). Early detection of beta-amyloid load in 
patients with suspected AD is vital to initiating early treatment, 
which can improve cognitive function and quality of life for many 
patients. The invention describes novel derivatives of 
imidazopyridinylbenzeneamine (IMPY) and benzothizolylbenzeneamine 
(BTA), which demonstrate high in vitro binding affinity to human 
beta-amyloid. The difference between existing IMPY compounds and the 
novel derivatives is the substitution of an aryl halide with an aryl 
thioether group and replacement of a sulfur group of the pyridine 
ring with a nitrogen group. The new classes of compounds have the 
potential of providing improved amyloid imaging agents for Positron 
Emission Tomography (PET) with higher specificity for amyloid, low 
background noise, better entry into the brain and improved labeling 
efficiency.
    Potential Commercial Applications:

 Alzheimer's disease
 Alzheimer's disease diagnostics
 Alzheimer's disease early detection

    Competitive Advantages: Specificity
    Development Stage: In vitro data available
    Inventors: Lisheng Cai, Victor W. Pike, Robert B. Innis (all of 
NIMH)
    Publications:

1. Nichols L, et al. Imaging and in vivo quantitation of beta-
amyloid: an exemplary biomarker for Alzheimer's disease? Biol 
Psychiatry. 2006 May 15;59(10):940-7. [PMID 16487944]
2. Toyama H, et al. PET imaging of brain with the beta-amyloid 
probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's 
disease. Eur J Nucl Med Mol Imaging. 2005 May;32(5):593-600. [PMID 
15791432]
3. Cai L, et al. Synthesis and evaluation of two 18F-labeled 6-iodo-
2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as 
prospective radioligands for beta-amyloid in Alzheimer's disease. J 
Med Chem. 2004 Apr 22;47(9):2208-18. [PMID 15084119]

    Intellectual Property: HHS Reference No. E-156-2006/0--

 US Patent Application 12/293,940 filed September 17, 2008 
(allowed)
 European Patent Application 07797254.5 filed April 19, 2007 
(pending)

    Related Technologies:

 HHS Reference No. E-136-2008/0--``Beta Amyloid PET Imaging 
Agents Based On 2-(4-phenyl)benzo[d]thiazole Derivatives''
 HHS Reference Nos. E-225-2011/0 and/1--``Beta-amyloid PET 
Imaging Agents Based On Benzothiazoles (BTA) Derivatives''

    Licensing Contact: Michael Shmilovich, Esq., CLP; 301-435-5019; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Mental Health is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate or commercialize Alzheimer's disease diagnostics. For 
collaboration opportunities, please contact Suzanne Winfield, Ph.D. 
at 301-402-4324.

    Dated: February 27, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-04771 Filed 3-4-14; 8:45 am]
BILLING CODE 4140-01-P